Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Mapping Your Future: Staging and Long-Term Monitoring

At a Glance

Long-term monitoring for differentiated thyroid carcinoma involves regular thyroglobulin (Tg) blood tests and neck ultrasounds to detect cancer recurrence. While your initial stage predicts survival, your ongoing risk level is regularly updated based on your response to treatment.

After your initial treatment for Differentiated Thyroid Carcinoma (DTC), your medical team shifts its focus from “curing” to “monitoring.” This phase uses two different systems to look at your health: one that predicts your overall survival (Staging) and one that predicts if the cancer might return (Risk Stratification) [1][2].

Understanding the “Downstaging” Effect

Doctors currently use the AJCC TNM 8th Edition to stage your cancer [3]. One of the most significant changes in this recent update was raising the age threshold for staging from 45 to 55 years old [4].

Because DTC has such a favorable prognosis in younger people, most patients under age 55 are now classified as Stage I, even if the cancer has spread to nearby lymph nodes [3][5]. This “downstaging” reflects the reality that for most people, DTC is a highly manageable disease with an excellent long-term outlook [1].

Predictors of Recurrence: The ATA Risk System

While staging tells you about survival, the American Thyroid Association (ATA) Risk Stratification system tells you how likely the cancer is to come back [2]. You will be placed into one of three categories:

  • Low Risk: Small tumors confined to the thyroid with no aggressive features [2].
  • Intermediate Risk: Tumors with some spread to neck lymph nodes or minor growth outside the thyroid [6][2].
  • High Risk: Larger tumors with extensive spread to lymph nodes or distant parts of the body [2].

Dynamic Risk Stratification: Your Evolving Status

The most important concept in your long-term care is Dynamic Risk Stratification (DRS) [7]. Unlike your initial stage, which never changes, your DRS is updated at every check-up based on your “Response to Therapy” [8][9].

There are four response categories:

  1. Excellent Response: Your scans show no signs of disease, and your tumor marker blood tests are stable and exactly where your doctor expects them to be [10][11].
  2. Indeterminate Response: You have vague findings on an ultrasound that aren’t clearly cancer, or low-level but ambiguous blood test results [10][12].
  3. Biochemical Incomplete Response: Your tumor marker blood levels are rising or suspiciously high, but no actual tumor can be found on scans [10][2].
  4. Structural Incomplete Response: A tumor or enlarged lymph node is visible on an ultrasound or other imaging [10][13].

The Monitoring Roadmap

Your “survivorship” schedule will be tailored to your risk level but generally includes two main tools [14]:

  • Thyroglobulin (Tg) Blood Tests: Thyroglobulin is a protein produced by thyroid tissue, often used as your “cancer marker.” Crucially, what your doctor expects your Tg to be depends entirely on your surgery:
    • If your entire thyroid was removed, your Tg should ideally be near zero [15].
    • If you had a lobectomy (partial removal), you will naturally have measurable Tg produced by your remaining healthy thyroid lobe. In this case, your doctor is simply looking for a stable number that isn’t rapidly rising.
  • Thyroglobulin Antibodies (TgAb): The immune system sometimes creates antibodies that attack thyroglobulin. If present, they can artificially lower or interfere with your Tg test results, potentially masking a recurrence. Doctors always check TgAb alongside Tg to ensure the test is accurate.
  • Neck Ultrasounds: Used to look for any changes in the “thyroid bed” or nearby lymph nodes [14].

In the beginning, these tests may happen every 6 months, but as you maintain an “Excellent Response,” your doctor may move them to once a year or even less frequently [14][16].

Managing “Scanxiety”

It is completely normal to feel a spike in distress around the time of your follow-up tests—a phenomenon often called scanxiety [17]. Research shows this is most intense in the “waiting period” between having the scan and receiving the results [18][19].

To help manage this, you can ask your care team for clear timelines on when results will be available or request a same-day review of labs [20][21]. Remember that for most DTC patients, monitoring is a safety net designed to catch very small changes long before they become a threat to your health.

Common questions in this guide

Why did my thyroid cancer stage change because of my age?
The staging system for differentiated thyroid carcinoma uses age 55 as a cutoff because younger patients have an exceptionally high survival rate. Most patients under 55 are classified as Stage I, even if the cancer has spread to nearby lymph nodes, reflecting the excellent long-term outlook.
What is the difference between my cancer stage and my ATA risk level?
Your cancer stage helps your doctor predict your overall survival and long-term prognosis. In contrast, the American Thyroid Association (ATA) risk level predicts how likely the cancer is to come back. While your initial stage never changes, your risk level can change based on your ongoing test results.
What should my thyroglobulin (Tg) level be after treatment?
Your target thyroglobulin level depends entirely on the type of surgery you had. If your entire thyroid was removed, your Tg should ideally be near zero. If you only had a partial removal, your remaining healthy tissue will naturally produce some thyroglobulin, so your doctor will look for a stable number.
Why does my doctor check for thyroglobulin antibodies (TgAb)?
Your immune system can sometimes create antibodies that attack thyroglobulin. If these are present in your blood, they can artificially lower your test results and potentially hide a cancer recurrence. Doctors always measure TgAb alongside thyroglobulin to ensure your test results are completely accurate.
Is it normal to feel anxious before my follow-up tests?
Yes, it is very common to experience distress or "scanxiety" before and during your follow-up appointments. This anxiety is often highest while waiting for your test results. You can help manage this by asking your care team for clear timelines on when your lab and scan results will be available.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the 8th edition staging, what is my numerical stage (I, II, etc.) and what does that mean for my overall prognosis?
  2. 2.Was my initial risk of recurrence classified as Low, Intermediate, or High by the ATA guidelines?
  3. 3.Which of the four 'Response to Therapy' categories do I currently fall into based on my latest labs and scans?
  4. 4.What is my current Tg level, and is my TgAb negative or positive?
  5. 5.Can we schedule a 'results call' for my next scan in advance to minimize the time I spend waiting for results?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.

    van Velsen EFS, Stegenga MT, van Kemenade FJ, et al.

    Thyroid : official journal of the American Thyroid Association 2018; (28(8)):976-981 doi:10.1089/thy.2018.0066.

    PMID: 29848239
  2. 2

    Differentiated Thyroid Cancer with Biochemical Incomplete Response: Clinico-Pathological Characteristics and Long Term Disease Outcomes.

    Steinschneider M, Pitaro J, Koren S, et al.

    Cancers 2021; (13(21)) doi:10.3390/cancers13215422.

    PMID: 34771585
  3. 3

    Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.

    Kim K, Kim JK, Lee CR, et al.

    Therapeutic advances in endocrinology and metabolism 2020; (11()):2042018820921019 doi:10.1177/2042018820921019.

    PMID: 32489582
  4. 4

    Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.

    Trimboli P, Piccardo A, Signore A, et al.

    Thyroid : official journal of the American Thyroid Association 2020; (30(5)):713-719 doi:10.1089/thy.2019.0688.

    PMID: 31973653
  5. 5

    How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?

    Alzahrani AS, Albalawi L, Mazi S, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(6)):607-613 doi:10.1016/j.eprac.2020.11.018.

    PMID: 34120701
  6. 6

    Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease.

    Sapuppo G, Hartl D, Fresneau B, et al.

    Cancers 2021; (13(15)) doi:10.3390/cancers13153732.

    PMID: 34359632
  7. 7

    Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma.

    Kim K, Kim WW, Choi JB, et al.

    Annals of surgical treatment and research 2018; (95(4)):222-229 doi:10.4174/astr.2018.95.4.222.

    PMID: 30310805
  8. 8

    Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah.

    Jasim MS, Hussein IH, Alidrisi HA, Mansour AA

    Cureus 2023; (15(10)):e47990 doi:10.7759/cureus.47990.

    PMID: 38034160
  9. 9

    Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?

    Krajewska J, Chmielik E, Jarząb B

    Endocrine-related cancer 2017; (24(11)):R387-R402 doi:10.1530/ERC-17-0270.

    PMID: 28821573
  10. 10

    Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.

    Momesso DP, Vaisman F, Yang SP, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(7)):2692-700 doi:10.1210/jc.2015-4290.

    PMID: 27023446
  11. 11

    Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis.

    Grani G, D'Elia S, Puxeddu E, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(5)):e1377-e1384 doi:10.1210/clinem/dgae559.

    PMID: 39150986
  12. 12

    Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.

    Oh HS, Ahn JH, Song E, et al.

    Thyroid : official journal of the American Thyroid Association 2019; (29(2)):209-215 doi:10.1089/thy.2018.0391.

    PMID: 30384812
  13. 13

    SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.

    Deng Y, Zhu G, Ouyang W, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(9)):887-898 doi:10.4158/EP-2018-0583.

    PMID: 31170371
  14. 14

    Contribution of neck ultrasonography to patient management in patients with differentiated thyroid carcinoma with excellent response to therapy.

    Hekimsoy İ, Güven M, Tokaç RH, et al.

    Endocrine 2025; (88(1)):135-142 doi:10.1007/s12020-024-04147-x.

    PMID: 39738889
  15. 15

    The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer.

    Szujo S, Bajnok L, Bodis B, et al.

    Cancers 2021; (13(2)) doi:10.3390/cancers13020310.

    PMID: 33467717
  16. 16

    Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission?

    Lamartina L, Handkiewicz-Junak D

    European journal of endocrinology 2020; (182(5)):D1-D16.

    PMID: 32197235
  17. 17

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  18. 18

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  19. 19

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  20. 20

    "You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

    Derry-Vick H, Prigerson HG, Hahne J, et al.

    Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

    PMID: 41338711
  21. 21

    Alone with the diagnosis: A reflective analysis on imaging report access and emotional burden.

    Chau M

    Radiography (London, England : 1995) 2025; (31 Suppl 2()):103104 doi:10.1016/j.radi.2025.103104.

    PMID: 40764216

This page explains staging and monitoring protocols for differentiated thyroid carcinoma for educational purposes only. Always consult your oncology or endocrinology care team to interpret your specific scan and laboratory results.

Get notified when new evidence is published on Differentiated thyroid carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.